FDA Approves Solesta to Treat Life-Altering Fecal Incontinence

The FDA has approved Solesta as a treatment for fecal incontinence in adult patients who have failed conservative therapy such as dietary control, according to a release from Oceana Therapeutics, the maker of Solesta.

Advertisement

 

The new product, developed in collaboration with Q-Med AB, is a minimally invasive, injectable gel that can be administered relatively quickly in an outpatient setting without the need for anesthesia.

 

Oceana plans to focus marketing and medical educational of Solesta on colorectal surgeons, according to the release.

 

Read the Oceana release on Solesta.

 

Related Articles on Incontinence:

FDA Gastroenterology and Urology Device Panel Approves Fecal Incontinence Product

10 Managed Care Best Practices for Bariatrics, General Surgery and Gynecology

Allergan Seeks Approval for Lap-Band Surgery for Less Obese Patients

 

 

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Register to Attend Webinar

Building a High-Performance Cardiac PET Program: What Health Systems Should Consider

Thursday, July 30
12:00 PM - 1:00 PM CDT

Presenters: Rupa Sanghani, MD, FACC, FASNC, Rush University Medical CenterBrendon Loiselle, CDL Nuclear Technologies

Advertisement

Next Up in GI & Endoscopy

Advertisement

Comments are closed.